Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MEDI7510 in Older Adults
NCT02289820Phase 1Completed
- Sponsor
- MedImmune
- Start
- Jan 2015
- Primary completion
- Feb 2016
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI7510 in respiratory syncytial virus infection (RSV) (10 cohorts), sponsored by MedImmune. Primary endpoints: Percentage of Participants With Solicited Symptoms, Percentage of Participants With Treatment-emergent Adverse Events and 3 more. Started Jan 2015; status: completed.
02
Drugs
MEDI7510
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02289820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289820.